Advancing Patient-Centric Drug Delivery For Neurodegenerative Disease With Orally Dissolving Tablets

By Ralph Gosden, Head of Product Development, Catalent

The economic burden of medication non-compliance in the United States is estimated to reach nearly $300 billion annually, and this issue is projected to intensify in the coming years. To address this growing concern, the pharmaceutical industry is increasingly prioritizing patient-centric drug development and design. By considering patient-friendly dosage forms early in the drug development process, companies aim to enhance patient compliance and adherence.

Key factors such as product acceptability and patient preference play a critical role in ensuring compliance and achieving optimal therapeutic outcomes. As the global population continues to age, challenges such as difficulty in swallowing, or dysphagia, have become significant barriers to medication adherence. Traditional oral dosage forms like tablets and capsules are often difficult to swallow, particularly for patients with neurodegenerative conditions such as Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis (ALS).

To address these challenges, orally dissolving tablets (ODTs) have emerged as a promising solution. Designed to dissolve rapidly in the mouth without the need for water, ODTs offer a convenient and patient-friendly alternative that has gained widespread recognition. These dosage forms are particularly well-suited for individuals with dysphagia, providing ease of administration while improving the overall patient experience. By addressing both the physical and psychological barriers to medication compliance, ODTs not only enhance patient adherence but also support better therapeutic outcomes.